Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.32 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | DRD1 | P21728 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346917 | 0.88 | SHBG (0.40) | SHBGMDM2ESR2ESR1DRD1 | |
| SCHEMBL1346890 | 0.88 | SHBG (0.40) | SHBGMDM2ESR2ESR1DRD1 | |
| SCHEMBL1346920 | 0.88 | SHBG (0.40) | SHBGMDM2ESR2ESR1DRD1 | |
| SCHEMBL1346787 | 0.88 | SHBG (0.40) | SHBGMDM2ESR2ESR1DRD1 | |
| SCHEMBL1346889 | 0.88 | SHBG (0.40) | SHBGMDM2ESR2ESR1DRD1 | |
| SCHEMBL12133292 | 0.85 | SHBG (0.44) | SHBGESR2ESR1DRD1SOAT1 | |
| SCHEMBL1347277 | 0.84 | SHBG (0.44) | SHBGMDM2ESR2ESR1SOAT1 | |
| SCHEMBL1346302 | 0.84 | SHBG (0.44) | SHBGMDM2ESR2ESR1SOAT1 | |
| SCHEMBL1347610 | 0.84 | SHBG (0.44) | SHBGMDM2ESR2ESR1SOAT1 | |
| SCHEMBL1346104 | 0.84 | NQO2 (0.41) | MDM2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406206-B1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | MSD OSS BV (NL) | 2013-01-30 | — | — | EP | disclosed |
| US-8063102-B2 | Tetrahydronaphthalen-2-ol derivatives | N.V. ORGANON (NL) | 2011-11-22 | — | — | US | disclosed |
| US-8063102-B2 | Tetrahydronaphthalen-2-ol derivatives | N.V. ORGANON (NL) | 2011-11-22 | — | — | US | disclosed |
| US-8063102-B2 | Tetrahydronaphthalen-2-ol derivatives | N.V. ORGANON (NL) | 2011-11-22 | — | — | US | disclosed |
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | N. V. ORGANON | 2010-09-23 | — | — | US | disclosed |
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | N. V. ORGANON | 2010-09-23 | — | — | US | disclosed |
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | N. V. ORGANON | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | VHL, BRCA1, TPH2 | SHBG 31/4885MDM2 802/4885ESR2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.